Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vsee Health (VSEE) EBITDA (2023 - 2025)

Vsee Health filings provide 3 years of EBITDA readings, the most recent being $3.1 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 201.35% to $3.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.1 million, a 94.99% increase, with the full-year FY2025 number at -$3.1 million, up 95.05% from a year prior.
  • EBITDA hit $3.1 million in Q4 2025 for Vsee Health, up from -$2.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $3.1 million in Q4 2025 to a low of -$58.3 million in Q3 2024.
  • Median EBITDA over the past 3 years was -$715855.0 (2023), compared with a mean of -$6.0 million.
  • Biggest five-year swings in EBITDA: tumbled 16411.08% in 2024 and later surged 201.35% in 2025.
  • Vsee Health's EBITDA stood at -$114831.0 in 2023, then tumbled by 2536.38% to -$3.0 million in 2024, then surged by 201.35% to $3.1 million in 2025.
  • The last three reported values for EBITDA were $3.1 million (Q4 2025), -$2.1 million (Q3 2025), and -$2.3 million (Q2 2025) per Business Quant data.